Search research articles
Contact Us
Filters
Showing results (21-30 of 64) with videos related to
Page
of 7
Sort By:
Molecular Medicine (Cambridge, Mass.)
|
September 1, 2015
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma
YanGuo Kong, Gustavo A Barisone, Ranjit S Sidhu, et al.
Investigational New Drugs
|
March 24, 2009
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
Robert T O'Donnell, Shiloh M Martin, Yunpeng Ma, et al.
Journal of Autoimmunity
|
November 7, 2002
Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect
Joseph M Tuscano, Tom C Hsu, Hayes McKnight, et al.
Leukemia Research
|
October 9, 2012
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
Jason Kato, Noriko Satake, Robert T O'Donnell, et al.
International Journal of Molecular Sciences
|
July 27, 2024
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo
Joshua F Meckler, Daniel J Levis, Yanguo Kong, et al.
Leukemia Research
|
September 22, 2014
Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7
YanGuo Kong, Gustavo A Barisone, Mastewal Abuhay, et al.
Leukemia & Lymphoma
|
December 27, 2013
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
Mark H Kirschbaum, Kenneth A Foon, Paul Frankel, et al.
Cancer Immunology, Immunotherapy : CII
|
August 11, 2016
The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity
Mastewal Abuhay, Jason Kato, Emily Tuscano, et al.
Journal of Hematology & Oncology
|
December 2, 2011
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
Shiloh M Martin, Eric Churchill, Hayes McKnight, et al.
Plos One
|
January 6, 2018
A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation
Gustavo A Barisone, Robert T O'Donnell, Yunpeng Ma, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 64) with videos related to
Sort By:
Page
of 7
Molecular Medicine (Cambridge, Mass.)
|
September 1, 2015
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma
YanGuo Kong, Gustavo A Barisone, Ranjit S Sidhu, et al.
Investigational New Drugs
|
March 24, 2009
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
Robert T O'Donnell, Shiloh M Martin, Yunpeng Ma, et al.
Journal of Autoimmunity
|
November 7, 2002
Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect
Joseph M Tuscano, Tom C Hsu, Hayes McKnight, et al.
Leukemia Research
|
October 9, 2012
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
Jason Kato, Noriko Satake, Robert T O'Donnell, et al.
International Journal of Molecular Sciences
|
July 27, 2024
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo
Joshua F Meckler, Daniel J Levis, Yanguo Kong, et al.
Leukemia Research
|
September 22, 2014
Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7
YanGuo Kong, Gustavo A Barisone, Mastewal Abuhay, et al.
Leukemia & Lymphoma
|
December 27, 2013
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
Mark H Kirschbaum, Kenneth A Foon, Paul Frankel, et al.
Cancer Immunology, Immunotherapy : CII
|
August 11, 2016
The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity
Mastewal Abuhay, Jason Kato, Emily Tuscano, et al.
Journal of Hematology & Oncology
|
December 2, 2011
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner
Shiloh M Martin, Eric Churchill, Hayes McKnight, et al.
Plos One
|
January 6, 2018
A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation
Gustavo A Barisone, Robert T O'Donnell, Yunpeng Ma, et al.
Page
of 7